Kirsten Salado-Rasmussen1, Jørgen Skov Jensen1. 1. Microbiology and Infection Control, Sexually Transmitted Infections, Research and Development, Statens Serum Institut, Copenhagen, Denmark.
Abstract
BACKGROUND: Mycoplasma genitalium is a common cause of nongonococcal urethritis (NGU) and cervicitis. The aim of the study was to analyze the M. genitalium testing pattern and distribution of positive results according to sex and age in a 5-year period where all diagnostic M. genitalium testing in Denmark was centralized at the Statens Serum Institut. A secondary aim was to estimate the occurrence of macrolide resistance in a 3-year period. METHODS: The study was performed as a nationwide retrospective survey of specimens submitted from general practice, private specialists, and hospitals to Statens Serum Institut for detection of M. genitalium by polymerase chain reaction between 1 January 2006 and 31 December 2010. Macrolide resistance screening was introduced December 2007. RESULTS: A total of 31 600 specimens from 28 958 patients were tested for M. genitalium, with an increasing trend from 3858 per year in 2006 to 7361 in 2010. The majority (54%) of the patients were tested in general practice. For both sexes, the positive rate increased significantly, from 2.4% to 3.8% for women and from 7.9% to 10.3% for men (P < .0005). Macrolide resistance was detected in 38% (385/1008) of the M. genitalium-positive patients, and the highest rate was found in patients tested at sexually transmitted disease clinics (43%). CONCLUSIONS: Testing for M. genitalium has become important for clinicians treating sexually transmitted infections. In this nationwide survey, macrolide resistance was found in almost 40% of the specimens, raising concern about single-dose azithromycin treatment of NGU, and emphasizing that NGU treatment should be guided by etiologic diagnosis.
BACKGROUND:Mycoplasma genitalium is a common cause of nongonococcal urethritis (NGU) and cervicitis. The aim of the study was to analyze the M. genitalium testing pattern and distribution of positive results according to sex and age in a 5-year period where all diagnostic M. genitalium testing in Denmark was centralized at the Statens Serum Institut. A secondary aim was to estimate the occurrence of macrolide resistance in a 3-year period. METHODS: The study was performed as a nationwide retrospective survey of specimens submitted from general practice, private specialists, and hospitals to Statens Serum Institut for detection of M. genitalium by polymerase chain reaction between 1 January 2006 and 31 December 2010. Macrolide resistance screening was introduced December 2007. RESULTS: A total of 31 600 specimens from 28 958 patients were tested for M. genitalium, with an increasing trend from 3858 per year in 2006 to 7361 in 2010. The majority (54%) of the patients were tested in general practice. For both sexes, the positive rate increased significantly, from 2.4% to 3.8% for women and from 7.9% to 10.3% for men (P < .0005). Macrolide resistance was detected in 38% (385/1008) of the M. genitalium-positive patients, and the highest rate was found in patients tested at sexually transmitted disease clinics (43%). CONCLUSIONS: Testing for M. genitalium has become important for clinicians treating sexually transmitted infections. In this nationwide survey, macrolide resistance was found in almost 40% of the specimens, raising concern about single-dose azithromycin treatment of NGU, and emphasizing that NGU treatment should be guided by etiologic diagnosis.
Authors: Craig R Cohen; Lisa E Manhart; Elizabeth A Bukusi; Sabina Astete; Robert C Brunham; King K Holmes; Samuel K Sinei; Job J Bwayo; Patricia A Totten Journal: Lancet Date: 2002-03-02 Impact factor: 79.321
Authors: Kaitlin A Tagg; Neisha J Jeoffreys; Deborah L Couldwell; Jennifer A Donald; Gwendolyn L Gilbert Journal: J Clin Microbiol Date: 2013-05-08 Impact factor: 5.948
Authors: H F Clausen; J Fedder; M Drasbek; P K Nielsen; B Toft; H J Ingerslev; S Birkelund; G Christiansen Journal: Hum Reprod Date: 2001-09 Impact factor: 6.918
Authors: I Simms; K Eastick; H Mallinson; K Thomas; R Gokhale; P Hay; A Herring; P A Rogers Journal: Sex Transm Infect Date: 2003-04 Impact factor: 3.519
Authors: Marcus J Pond; Achyuta V Nori; Adam A Witney; Rose C Lopeman; Philip D Butcher; Syed Tariq Sadiq Journal: Clin Infect Dis Date: 2013-11-26 Impact factor: 9.079
Authors: Jennifer E Balkus; Lisa E Manhart; Jørgen S Jensen; Omu Anzala; Joshua Kimani; Jane Schwebke; Juma Shafi; Charles Rivers; Emanuel Kabare; R Scott McClelland Journal: Sex Transm Dis Date: 2018-08 Impact factor: 2.830
Authors: Maria Trent; Jenell S Coleman; Justin Hardick; Jamie Perin; Lisa Tabacco; Steven Huettner; Jocelyn Ronda; Rebecca Felter-Wernsdorfer; Charlotte A Gaydos Journal: Sex Transm Infect Date: 2018-03-29 Impact factor: 3.519
Authors: Laura C Chambers; James P Hughes; Sara N Glick; Jennifer L Morgan; M Sylvan Lowens; Tashina S Robinson; Sarah S Romano; Gina L Leipertz; Jørgen S Jensen; Christine M Khosropour; David N Fredricks; Matthew R Golden; Lisa E Manhart Journal: Sex Transm Dis Date: 2019-10 Impact factor: 2.830
Authors: Sarah S Romano; Jørgen S Jensen; M Sylvan Lowens; Jennifer L Morgan; Laura C Chambers; Tashina S Robinson; Patricia A Totten; Olusegun O Soge; Matthew R Golden; Lisa E Manhart Journal: Clin Infect Dis Date: 2019-06-18 Impact factor: 9.079